The Cell Medica Approach
Cell Medica is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies.
Our approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called Natural Killer T cells (NKT cells) and innovative CAR construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors.
Senior Management Team
Kevin has over 20 years of diversified finance experience helping companies define and achieve strategic financial objectives. He has broad international experience with both public and private companies and has raised over $2.0 billion in capital over his career.
Before joining Cell Medica, Kevin served as Chief Financial Officer of FloWorks International and had held previous senior finance roles at Sigma Cubed, RecoverCare and SPT. Kevin graduated from Carnegie Mellon University with a B.S. in Industrial Management, and earned his J.D. from the University of Pennsylvania. He is active in the Houston community, serving as Treasurer of The Center for Hearing and Speech and on the Advisory Board of the Hermann Park Conservancy.
Kurt has devoted his career to the development of cell and gene therapies and brings significant commercial experience to Cell Medica from his previous positions at Hospira, ViaCell, and Transkaryotic Therapies. At Cell Medica, Kurt is in charge of Clinical Operations, Medical and Scientific Affairs and Regulatory Affairs.
As past President of the International Society for Cellular Therapy (ISCT), Kurt played a worldwide leadership role in promoting understanding of the clinical, regulatory, manufacturing, and marketing requirements for the successful development of cell and gene therapies. Prior to his biotech career, he worked at the United States Food and Drug Administration as a Medical Officer in the Center for Biologics and was appointed Acting Deputy Director of the Division of Cell and Gene Therapy within the Center for Biologics Evaluation and Research.
Kurt earned his MD from the University of Kansas and also has a BS in biological sciences, with distinction, from Stanford University. His postdoctoral training included Johns Hopkins and the US National Institutes of Health.
Board of Directors
Annalisa Jenkins, MBBS, FRCP, joined the Board of Directors as Chairperson in December 2017. Prior to joining Cell Medica, Dr. Jenkins served as President and CEO of Dimension Therapeutics and held multiple leadership positions, including Executive Vice President, Head of Global Research and Development for Merck Serono, where she led global medical affairs and quality and was a member the Pharmaceutical Executive Committee.
Prior to this, Dr. Jenkins had a successful 14-year career at Bristol-Myers Squibb (BMS), attaining the role of Senior Vice President and Head of Global Medical Affairs. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital, University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service. Dr. Jenkins is a board member of several growing companies and a member of the Science Board to the U.S. Food & Drug Administration (FDA). She also serves on the board of the Center for Talent Innovation in the U.K.
Sam is Managing Partner, Life Sciences, at IP Group plc. He has 20 years’ experience in the biotech sector, both as a top-ranked equity analyst in the City of London and, subsequently, as a chief executive and non-executive director. He currently serves as Executive Chairman of Istesso Ltd, Chairman of Glythera Ltd and Microbiotica Ltd, and as a director of Diurnal Group plc. Sam has a PhD in molecular biology from Cambridge and a degree in biology from Oxford.
Thomas has been on the Cell Medica Board since 2012 and he was Chairman until December 2017. He was previously Vice President Marketing at Amgen Europe, Lucerne, Switzerland. Following his academic career, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he served as Co-Head of the Program for Bone Marrow Transplantation, University of Freiburg, Germany.
Julia P. Gregory, Chairman and CEO of Isometry Advisors, Inc., a biotechnology financial and management advisory firm, has 16 years of executive management experience and 20 years of investment banking experience. As an executive, she successfully raised more than $1.5 billion for her companies through initial public offerings, public and private offerings and creative strategic alliances including GlaxoSmithKline, BristolMyers Squibb, Takeda Pharmaceuticals, Genentech, (Roche) and Human Genome Sciences (GSK), among others.
She was formerly CEO of the novel antibiotics company, ContraFect Corporation, CEO of FivePrime Therapeutics, an immuno-oncology company, and EVP, Head of Corporate Development and CFO of Lexicon Pharmaceuticals where she lead the Company’s $220 million IPO. She is currently on the board of directors of Iconic Therapeutics, IMV Corporation, the Sosei Group and Biohaven Therapeutics. Ms. Gregory attained a Masters of Business Administration from the Wharton School at the University of Pennsylvania, and earned her B.A. at the George Washington University.